

Disclosure Purpose: 21-03784

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
National Institutes of Health	Grant / Contract	Self
<i>Recipient Name:</i> University of Michigan <i>Grant / Contract Description:</i> U 01 <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Convalescent Plasma for High-Risk Outpatients with Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Convalescent Plasma for High Risk Patients with COVID-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early convalescent plasma for high risk out patients with COVID-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-03784

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Biomedical Advanced Research and Development Authority	Grant / Contract	Other - Grant to Vitalant
<i>Recipient Name:</i> Vitalant Research Institute <i>Grant / Contract Description:</i> 75A50120C00094 <i>Additional Information:</i> Provide material support to research		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
National Heart, Lung, and Blood Institute	Grant / Contract	Self
<i>Recipient Name:</i> University of Pittsburgh <i>Grant / Contract Description:</i> 10T2HL156812-01 <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
National Institute of Neurological Disorders and Stroke	Grant / Contract	Self
<i>Recipient Name:</i> University of Michigan and Medical University of South Carolina <i>Grant / Contract Description:</i> U24NS100659 and U24NS100655 <i>Additional Information:</i> Infrastructure for SIREN clinical trial network		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Intellectual Property

Type	Is Licensed	Interest Held By
Patent - Methods and devices to guide therapy for ventric ...	No	Self
<i>Description:</i> Methods and devices to guide therapy for ventricular fibrillation based on waveform analysis and sur <i>Patent Holder:</i> Discloser <i>Licensees:</i>		<i>Patent Number:</i> US7269454B2 <i>Patent Status:</i> Issued <i>Filing Jurisdiction:</i> USA <i>Additional Information:</i>
Patent - Method and apparatus employing a scaling exponen ...	No	Self
<i>Description:</i> Method and apparatus employing a scaling exponent for selectively defibrillating a patient <i>Patent Holder:</i> Current Institution <i>Licensees:</i>		<i>Patent Number:</i> US6438419B1 <i>Patent Status:</i> Issued <i>Filing Jurisdiction:</i> USA <i>Additional Information:</i> No revenue
Patent - Electrocardiographic identification of non-st el ...	No	Self
<i>Description:</i> Electrocardiographic identification of non-st elevation ischemic events <i>Patent Status:</i> Issued <i>Filing Jurisdiction:</i> USA <i>Licensees:</i>		<i>Patent Number:</i> WO2016168181A1 <i>Patent Holder:</i> Current Institution <i>Additional Information:</i> No revenue

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**

No.

2. **What is the manuscript title?**

Early Convalescent Plasma for High Risk Outpatients with Covid-19

3. **Are you the corresponding author?**

Yes.

a. **Please list the other authors' names here.**

Frederick K. Korley, MD, PhD, University of Michigan Valerie Durkalski-Mauldin, PhD, Medical University of South Carolina Sharon D. Yeatts, PhD, Medical University of South Carolina Kevin Schulman, MD, MBA, Stanford University Robertson D. Davenport, MD, University of Michigan Larry J. Dumont, MBA, PhD, Vitalant Research Institute Nahed El Kassir, MD, PhD, National Heart Lung and Blood Institute Lydia D. Foster, MS, Medical University of South Carolina Jennifer M. Hah, MD, Stanford University Siddhartha Jaiswal, MD, PhD, Stanford University Alesia Kaplan, MD, University of Pittsburgh Ezekiel Lowell, BS, Medical University of South Carolina John F. McDyer, MD, University of Pittsburgh James Quinn, MD, Stanford University Darrell J. Triulzi, MD, University of Pittsburgh Carol Van Huysen, BS, University of Michigan Valerie LW Stevenson, BAS, RRT, University of Michigan Kabir Yadav, MDCM, MS, MSHS, Harbor-UCLA Medical Center Christopher W. Jones, MD, Cooper University Hospital Bory Kea, MD, Oregon Health and Science University Aaron Burnett, MD, Health Partners Methodist Hospital Joshua C.

Reynolds, MD, MS, Spectrum Health; Michigan State University Colin F. Greineder, MD, PhD, University of Michigan Nathan L. Haas, MD, University of Michigan David G. Beiser, MD, University of Chicago Robert Silbergleit, MD, University of Michigan William Barsan, MD, University of Michigan

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Convalescent Plasma for High Risk outpatients with Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-03784

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AVRO Bio	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Consultant for AVRO for research related to clonal hematopoiesis
Foresite Labs	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Consultant for Foresite Labs for research related to clonal hematopoiesis
Genentech	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Consultant for Genentech for research related to clonal hematopoiesis
Novartis	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Consultant for Novartis for research related to clonal hematopoiesis

Additional Questions:

1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
2. **What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with Covid-19
3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-03784

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
AstraZeneca	Grant / Contract	Self
<i>Recipient Name:</i> Cooper University Healthcare <i>Grant / Contract Description:</i> Research study testing anti-platelet agents in acute coronary syndrome <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Janssen Biotech, Inc.	Grant / Contract	Self
<i>Recipient Name:</i> Cooper University Healthcare <i>Grant / Contract Description:</i> Clinical trial involving patients with pulmonary embolism <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
Vapotherm Inc	Grant / Contract	Self
<i>Recipient Name:</i> Cooper University Healthcare <i>Grant / Contract Description:</i> Clinical trial involving patients with COPD <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Convalescent plasma for high risk outpatients with COVID-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with COVID-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-03784

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
AltitudeVentures	Other Securities	Self
<i>Security Description:</i> Limited Partner		<i>Additional Information:</i>
Business Roundtable	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Completed		<i>Description:</i> Literature review
Business SchoolAlliance for Health Management	Fiduciary Officer	Self
<i>Official Title:</i> President <i>Additional Information:</i>		<i>Position Description:</i> Not Compensated
Catalysis,Inc.	Fiduciary Officer	Self
<i>Official Title:</i> Board Member <i>Additional Information:</i>		<i>Position Description:</i> Uncompensated
CivicaRx	Other	Self
<i>Category:</i> Other <i>Additional Information:</i>		<i>Description:</i> Advisory Board
Cytokinetics	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Completed		<i>Description:</i> Honorarium for Talk
Excelebrate HealthVentures	Other Securities	Self
<i>Security Description:</i> Passive Investment in a Fund		<i>Additional Information:</i>
FacultyConnection	Fiduciary Officer	Self
<i>Official Title:</i> Managing Member, Shareholder <i>Additional Information:</i>		<i>Position Description:</i> Lead organization; all profits donated to charity.
Frazier Healthcare	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Review as part of due diligence
GRID Therapeutics	Stock Option	Self
<i>Additional Information:</i> Board Member		
Health Services Research	Fiduciary Officer	Self
<i>Official Title:</i> Senior Associate Editor <i>Additional Information:</i>		<i>Position Description:</i> Compensated Editor
HealthQuest Capital, LLC	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> Completed		<i>Description:</i> Honorarium for a Talk
ISMIE	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i>		<i>Description:</i> Speaker Honorarium
MotleyRice,LLP	Expert Witness	Self
<i>Category:</i> Expert Witness <i>Additional Information:</i> Opioid Litigation		<i>Description:</i> Opioid and PBM lawsuits
Novartis	Consultant	Self

Category: Consultant
Additional Information: Completed

Description: Study Design Advise

Prealize	Stock Option	Self
----------	--------------	------

Additional Information:

Reserve Therapeutics	Fiduciary Officer	Self
----------------------	-------------------	------

Official Title: President
Additional Information:

Position Description: President of pre-revenue company

Intellectual Property

Type	Is Licensed	Interest Held By
Patent - Methods, systems, and computer readable media fo ...	Yes	Self

Description: Methods, systems, and computer readable media for dynamically selecting questions to be presented in

Patent Holder: Other Organization - UNC

Licensees:

Licensee	Title	Date
PressGaney	sale	1/1/19

Patent Number: 9,305,059

Patent Status: Issued

Filing Jurisdiction: USA

Additional Information:

Patent - Systems And Methods For Mobile Patient-Centric E ...	No	Self
---	----	------

Description: Systems And Methods For Mobile Patient-Centric Electronic Health Record Data.
Provision Filed April

Patent Holder: Previous Institution

Licensees:

Patent Number: PCT/US2017/027310

Patent Status: Pending

Filing Jurisdiction: USA

Additional Information:

Additional Questions:

1. Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
No.
2. What is the manuscript title?
Early Convalescent Plasma for High Risk Outpatients with Covid-19
3. Are you the corresponding author?
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Convalescent Plasma for High-Risk Outpatients with Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-03784

Summary of Interests

Company or Organization		
Entity	Type	Interest Held By
American Association for Respiratory Care	Other	Self
<i>Category:</i> Other <i>Additional Information:</i> There is no compensation or allegiance. I am invited on ad hoc basis		<i>Description:</i> Journal reviewer

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
"Early Convalescent Plasma for High Risk Outpatients with Covid-19"
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-03784

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
Fresenius Kabi USA, LLC	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> \$450/hour		<i>Description:</i> Medical Advisory Board
realta life sciences	Consultant	Self
<i>Category:</i> Consultant <i>Additional Information:</i> \$400/hour		<i>Description:</i> Medical Advisory Board

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Convalescent plasma for high risk outpatients with CVOID-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.



Disclosure Purpose: 21-03784

Summary of Interests

I do not have any interests to disclose at this time.

Additional Questions:

- 1. **Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- 2. **What is the manuscript title?**
Early Convalescent Plasma for High Risk Outpatients with Covid-19
- 3. **Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.

Disclosure Purpose: 21-03784

Summary of Interests

Company or Organization

Entity	Type	Interest Held By
C. R. Bard, Inc. & Subsidiaries	Data And Safety Monitoring	Self
<i>Category:</i> Data And Safety Monitoring <i>Additional Information:</i>		<i>Description:</i> Member of DSMB for INTREPID. Fees paid to institution
National Heart, Lung, and Blood Institute	Grant / Contract	Self
<i>Recipient Name:</i> Medical University of South Carolina <i>Grant / Contract Description:</i> Various, related to statistical and data coordination <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research
National Institute of Neurological Disorders and Stroke	Grant / Contract	Self
<i>Recipient Name:</i> Medical University of South Carolina <i>Grant / Contract Description:</i> Various grants related to statistical and data coordination <i>Additional Information:</i>		<i>Recipient Type:</i> Institution <i>Grant / Contract Purpose:</i> Research

Intellectual Property

Type	Is Licensed	Interest Held By						
Copyright - Editorial Board for Stroke	Yes	Self						
<i>Description:</i> Editorial Board for Stroke <i>Filing Jurisdiction:</i> <i>Licensees:</i>		<i>Copyright Number:</i> <i>Copyright Holder:</i> <i>Additional Information:</i>						
<table border="1"> <thead> <tr> <th>Licensee</th> <th>Title</th> <th>Date</th> </tr> </thead> <tbody> <tr> <td>American Stroke Association</td> <td></td> <td></td> </tr> </tbody> </table>	Licensee	Title	Date	American Stroke Association				
Licensee	Title	Date						
American Stroke Association								

Additional Questions:

- Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?**
No.
- What is the manuscript title?**
Early Convalescent Plasma for High-Risk Outpatients with Covid-19
- Are you the corresponding author?**
No.

Certification

I certify that the information provided in this disclosure is complete and accurate.